Derma Sciences on Track to Begin Phase 3 Program with DSC127 in December Following Meeting with FDA

Derma Sciences on Track to Begin Phase 3 Program with DSC127 in December Following Meeting with FDA

[at noodls] – Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration … more

View todays social media effects on DSCI

View the latest stocks trending across Twitter. Click to view dashboard

Share this post